Hims & Hers Shares Sensitive Data with Third Parties and the FTC Doesn’t Like It

The U.S. FTC sued telehealth company Hims & Hers, joined by California and Utah, alleging it shared consumers’ private health data with ad platforms owned by Meta and Snap and billed some customers for prescriptions without meaningful consultation. The FTC also alleges unclear refill and subscription cancellation practices. Hims said its privacy policy lets patients choose data use; its stock fell nearly 12% on Wednesday.

The FTC filed a lawsuit against telehealth company Hims & Hers (Hims & Hers Health, Inc.) alleging it disclosed private health information to third parties and used subscription practices consumers say were misleading. According to the FTC, there were over 4,800 complaints in five years. Complaints cited surprise subscription charges, refund denials, limited medical support, and hard-to-reach support.

The FTC, according to its July 29 complaint, is suing Hims & Hers Health over alleged deceptive practices in telehealth subscription enrollment and privacy. The FTC claims consumers were charged for automatically renewing prescription subscriptions without informed consent, faced unclear refill timing and difficult cancellation, and were misled about how sensitive data was handled. The FTC seeks injunctions and monetary remedies.

Hims & Hers Health (HIMS) said it added eight partners to its Hims & Hers Benefits program, covering fitness, nutrition, preventive health and glucose monitoring. It integrated Dexcom’s Stelo with discounts passed to subscribers. HIMS shares rose about 1% and analysts at BofA cut its price target to $25. For 2026, Hims forecasts $2.8B to $3.0B revenue and $275M to $350M EBITDA.

Hinge Health reported Q2 2026 revenue up 53% year over year, citing higher yield from targeted enrollment and referrals. Operating margin rose 1,000 bps to 29%. Full-year 2026 revenue guidance increased to $856 million-$860 million. Hinge plans to expand beyond MSK via a $105 million acquisition of Cylinder Health, expected to add $7 million-$8 million in 2026 revenue and lift margins over 1-2 years.

Kirby McInerney LLP said it is investigating potential securities-fraud claims against Hims & Hers Health, Inc. (NYSE: HIMS). The probe follows an FTC lawsuit filed July 29, 2026 alleging Hims shared customers’ medical information with third-party advertisers, including Meta Platforms. After the news, Hims shares fell $4.32, or 14.73%, to $25.00.